Chan, "Human leukocyte antigen class i expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy
," British Journal of Cancer, vol.
Is it time to discontinue using high-dose chemotherapy for salvage of patients with advanced germ-cell tumors failing first-line platinum chemotherapy
? Ann Oncol 2006;17:349-50http://dx.doi.org/10.1093/annonc/mdj036.
Women who possess the biomarker identified by the Yale Cancer Center team - a variant of the well-known KRAS oncogene - are three times more resistant to standard platinum chemotherapy
than women without the variant.
Fennec has a license agreement with Oregon Health and Science University (OHSU) for exclusive worldwide license rights to intellectual property directed to STS and its use for chemoprotection, including the prevention of ototoxicity induced by platinum chemotherapy
, in humans.
Merck announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the National Medical Products Administration in combination with pemetrexed and platinum chemotherapy
for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer, with no EGFR or ALK genomic tumor aberrations.
Javelin Ovarian 200 is a multicentre and randomised trial designed to assess the efficacy and safety of avelumab alone or in combination with PLD against PLD alone in 566 women with ovarian cancer that is resistant or refractory to platinum chemotherapy
They excluded studies that did not include a platinum chemotherapy
drug and those that used only fish extracts such as only EPA or only DHA.
The standard first-line chemotherapies, such as paclitaxel, gemcitabine, docetaxel, or vinorelbine, is usually used in combination with the platinum chemotherapy
compound, and the treatment has become the main adjuvant treatment for various cancers, including NSCLC, bladder cancer and pancreatic cancer.
KEYTRUDA, in combination with pemetrexed and platinum chemotherapy
, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
Eli Lilly (LLY) announced that the FDA has granted approval for a new indication for ALIMTA in combination with KEYTRUDA, developed and marketed by Merck (MRK), and platinum chemotherapy
for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer, or NSCLC, with no EGFR or ALK genomic tumor aberrations.
The European Commission has granted approval to US-based Merck for its anti-PD-1 therapy Keytruda (pembrolizumab) in combination with pemetrexed (ALIMTA) and platinum chemotherapy
intended for treating metastatic nonsquamous non-small cell lung cancer, it was reported on Tuesday.